Barbiturate use among migraine patients significantly decreased after initiating treatment with rimegepant, a calcitonin gene-related peptide (CGRP) antagonist used for migraine treatment and ...
Results from this study demonstrate a robust and clinically meaningful reduction in barbiturate use after the initiation of Nurtec ODT, providing an alternative migraine therapy for those who may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results